Cargando…
Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy
The novel strain of coronavirus that appeared in 2019, SARS-CoV-2, is the causative agent of severe respiratory disease, COVID-19, and the ongoing pandemic. As for SARS-CoV that caused the SARS 2003 epidemic, the receptor on host cells that promotes uptake, through attachment of the spike (S) protei...
Autor principal: | Inal, Jameel M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298154/ https://www.ncbi.nlm.nih.gov/pubmed/32542396 http://dx.doi.org/10.1042/CS20200623 |
Ejemplares similares
-
The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021) -
ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology
por: Gawish, Riem, et al.
Publicado: (2022) -
Neutralizing SARS-CoV-2
por: Poeschla, Eric
Publicado: (2020) -
Taking on SARS-CoV-2
por: Kučan Brlić, Paola, et al.
Publicado: (2022) -
A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
por: Kegler, Alexandra, et al.
Publicado: (2023)